ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,050.09
0.05%
US Tech 100
20,639.20
0.13%
다우존스 지수
44,709.05
-0.16%
Bitcoin
95,628.44
-0.25%
Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. IO Biotech Inc (IOBT) 시세

IO Biotech Inc

IO Biotech Inc (IOBT)

NASDAQ
0.8629
-0.036
( -4.00% )
업데이트: 05:42:49
15분 지연

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

프리미엄

주요 통계 및 세부정보

가격
0.8629
매수가
0.8601
매도가
0.8629
거래량
390,285
0.8104 일간 변동폭 0.935108
0.66 52주 범위 2.098
market_cap
56.849M
전일 종가
0.8989
개장가
0.89
최근 거래 시간
2
@
0.8629
마지막 거래 시간
05:42:51
재정 규모
US$ 335,105
VWAP
0.858616
평균 볼륨(3m)
565,702
발행 주식
65,880,914
배당수익률
-
주가수익률
-0.64
주당순이익(EPS)
-1.31
매출
-
순이익
-86.08M

IO Biotech Inc 정보

IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced imm... IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
www.iobiotech.com
본부
Wilmington, Delaware, USA
설립됨
-
IO Biotech Inc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker IOBT. The last closing price for IO Biotech was US$0.90. Over the last year, IO Biotech shares have traded in a share price range of US$ 0.66 to US$ 2.098.

IO Biotech currently has 65,880,914 shares in issue. The market capitalisation of IO Biotech is US$59.22 million. IO Biotech has a price to earnings ratio (PE ratio) of -0.64.

IOBT 최신 뉴스

추가 뉴스

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

13 11월 2024
Edgar (US Regulatory)

Form 8-K - Current report

12 11월 2024
Edgar (US Regulatory)

IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with...

12 11월 2024
GlobeNewswire Inc.

IO Biotech Announces Participation in Upcoming Investor Conferences

NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines...

12 11월 2024
GlobeNewswire Inc.

IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study

-- Metastatic non-small cell lung cancer (NSCLC) patients treated in the first line setting with IO102-IO103 in combination with Keytruda® demonstrated promising activity with an overall response...

08 11월 2024
GlobeNewswire Inc.

IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines...

04 10월 2024
GlobeNewswire Inc.

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

-- Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the Head and Neck Cohort -- -- No New Safety...

14 9월 2024
GlobeNewswire Inc.

Form 8-K - Current report

31 8월 2024
Edgar (US Regulatory)

IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

- Based on a per-protocol interim analysis of safety and efficacy data, the Independent Data Monitoring Committee (IDMC) recommended that the trial continue without modifications- No new safety...

31 8월 2024
GlobeNewswire Inc.

IO Biotech Announces Participation in Upcoming Investor Conferences

NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its...

27 8월 2024
GlobeNewswire Inc.
기간변동변동 %시가고가저가평균 일일 거래량VWAP
10.102913.53947368420.760.950.714307680.84523206CS
4-0.2872-24.97174158771.15011.290.667600370.84048888CS
12-0.047101-5.17592837810.9100011.420.665657020.94323702CS
26-0.3371-28.09166666671.21.730.663668721.0406879CS
52-0.3571-29.27049180331.222.0980.662462471.17998077CS
156-8.9771-91.23069105699.8412.580.661435612.12894698CS
260-15.1371-94.6068751617.880.661438522.40732714CS

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
ZJKZJK Industrial Company Ltd
US$ 19.6613
(210.12%)
26.64M
CTNTCheetah Net Supply Chain Service Inc
US$ 5.12
(173.80%)
109.69M
GWAVGreenwave Technology Solutions Inc
US$ 0.6768
(85.42%)
495.78M
JYDJayud Global Logistics Ltd
US$ 1.10
(64.15%)
10.23M
JANXJanux Therapeutics Inc
US$ 59.965
(49.24%)
6.4M
REVBRevelation Biosciences Inc
US$ 0.5353
(-43.65%)
5.25M
OMEXOdyssey Marine Exploration Inc
US$ 0.4501
(-39.60%)
4M
STSSSharps Technology Inc
US$ 2.21
(-34.10%)
459.42k
AGFYAgrify Corporation
US$ 34.87
(-32.53%)
243.69k
CYCNCyclerion Therapeutics Inc
US$ 1.60
(-31.62%)
344.33k
GWAVGreenwave Technology Solutions Inc
US$ 0.6776
(85.64%)
495.86M
SMCISuper Micro Computer Inc
US$ 40.62
(-3.29%)
191.48M
NVDANVIDIA Corporation
US$ 139.97
(0.97%)
125.38M
CHRSCoherus BioSciences Inc
US$ 1.7999
(31.38%)
111.25M
CTNTCheetah Net Supply Chain Service Inc
US$ 5.12
(173.80%)
111.24M

IOBT Discussion

게시물 보기
ZLAZARUS ZLAZARUS 1 주 전
Ph3 melanoma data for IO102-IO103 remain on track for 1H25 and represents the next key catalyst. At .70 we are trading at cash. With a positive Ph3 melanoma readout we will be trading at $3.00 overnight with a march to $6.00 towards the later half of 2025. In addition, I'm encouraged by the supportive data in additional solid tumors which increases my confidence in the potential for success in the ongoing Ph3 melanoma study.

Also lets remember the IO102-IO103 melanoma study is with Merck's + pembrolizumab Ketruda. If IOBT's IO102-IO103 is approved, it will be a disruptive game changer thus creating an overnight valuation of about 200 million for the company in 2025. Leading into 2026, we could see a valuation conservatively of about $400M. This is my opinion.
👍️0
ZLAZARUS ZLAZARUS 2 주 전
Picked up at 20,000 shares @ .88 , I will pick up more when it drops below .73
👍️0
phrocks phrocks 2 주 전
Now you're a participant??
👍️0
ZLAZARUS ZLAZARUS 2 주 전
Targeting a fill between .70 & .78 Gem here on positive IOB-013/KN-D18 Q1 2025 Phase III results.
👍️0
Rkrocks Rkrocks 2 월 전
No real volume
👍️0
Rkrocks Rkrocks 2 월 전
Monk are we finally on the move with this?
👍️0
axelvento axelvento 2 월 전
O Biotech is developing a cancer vaccine that targets both the tumor and its microenvironment - a pivotal readout is coming in the first half of next year
Founder and CEO Mai-Britt Zocca explains the rationale for this dual focus and walks us through the lead program that targets PD-L1 and IDO, and which has breakthrough therapy designation. A pivotal study in first line metastatic melanoma will read out soon.

https://www.biotechtv.com/post/io-biotech-october-11-2024
👍️0
Monksdream Monksdream 2 월 전
IOBT under $2


👍️0
glenn1919 glenn1919 2 월 전
IOBT.................................https://stockcharts.com/h-sc/ui?s=IOBT&p=W&b=5&g=0&id=p86431144783
👍️0
axelvento axelvento 2 월 전
IOBiotech
is pleased to announce that it will be presenting two posters at the SITC 2024 Annual Meeting.

The first poster presentation contains updated and expanded data from the complete cohort (n=31) from the first line (1L) cohort of patients with PD-L1 high metastatic non-small cell lung cancer (NSCLC) in our Phase 2 basket trial of investigational IO102-IO103 in combination with pembrolizumab (KEYTRUDA®), Merck’s anti-PD-1 therapy. The second poster presentation contains new pre-clinical data for the next candidate in the IO Biotech pipeline, IO112, which targets Arginase 1.

We look forward to sharing these exciting data at the meeting which takes place in Houston from November 6-10, 2024. See full details here:

https://investors.iobiotech.com/news-events/news/news-details/2024/IO-Biotech-Announces-Two-Poster-Presentations-at-the-Society-for-Immunotherapy-of-Cancers-SITC-39th-Annual-Meeting/default.aspx
👍️0
glenn1919 glenn1919 3 월 전
iobt................................https://stockcharts.com/h-sc/ui?s=IOBT&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 3 월 전
IOBT new 52 week low
https://investorshub.advfn.com/uimage/uploads/2024/9/12/fmdniIMG_1694.gif
👍️0
Monksdream Monksdream 3 월 전
IOBT under $2
👍️0
PonkenPlonken PonkenPlonken 4 월 전
starting to run into the readout
Lead investigator and advisors that helped BMS in making ipi+nivo the new SOC --- They now work on this. Cancer vaccines back in fashion.
👍️0
PonkenPlonken PonkenPlonken 4 월 전
Sorry for the late reply, im not yet fully familiar with this platform.
The SOC for advanced melanoma is Ipi + Nivo which is neither very helpful nor very safe. Hence "the bar is hanging low" here.
👍️0
Monksdream Monksdream 4 월 전
IOBT
👍️0
stock1ace1 stock1ace1 5 월 전
Standard of care …
👍️0
Monksdream Monksdream 5 월 전
IOBT under $2
👍️0
ralfito ralfito 6 월 전
For us dummies, can you define SOC in this context? Thanks.
👍️0
PonkenPlonken PonkenPlonken 6 월 전
CEO made it pretty clear numerous times at Jefferies IMO
they will become the SOC, not only in advanced melanoma but in all stages.
They also think their platform can be used for non-cancer indications.

2 Birds in the hand and many more in the bush$$$
👍️0
PonkenPlonken PonkenPlonken 6 월 전
https://www.youtu be.com/watch?v=OvC-86SN9Ao&ab_channel=VJOncology

australian KOL on IOBT

many things pointing at it becoming the SOC one day...
👍️0
axelvento axelvento 6 월 전
golden cross MA50 MA200
👍️0
axelvento axelvento 7 월 전
a planned interim analysis of ORR will be conducted when the first 225 randomized patients reach one year of treatment in June 2024. The outcome of this analysis is expected in the third quarter of 2024 and, if supportive, we believe could allow for submission of a BLA for accelerated approval in the US.
Cash and cash equivalents as of March 31, 2024 were $118.0 million, compared to $143.2 million at December 31, 2023. During the three months ended March 31, 2024, the company used cash, cash equivalents and restricted cash of $24.9 million. The increase in cash use was primarily driven by milestone payments and payment of other accrued expenses associated with clinical trials, as well as the payment of year-end bonuses. The company continues to expect that it will have sufficient cash to run the company into the fourth quarter of 2025.
👍️0
axelvento axelvento 7 월 전
Completed enrollment of pivotal Phase 3 trial of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with KEYTRUDA® (pembrolizumab), in patients with advanced melanoma; planned interim analysis for overall response rate (ORR) expected in third quarter of 2024 by independent data monitoring committee
Progressed clinical development of IO102-IO103 with first patient dosed in Phase 2 basket trial of IO102-IO103 in combination with pembrolizumab as neoadjuvant and adjuvant treatment of patients with resectable solid tumors
Ended 2023 with cash and cash equivalents of approximately $143.2 million; expected operational runway into the fourth quarter of 2025

https://www.biopharmcatalyst.com/company/IOBT/news/190095
👍️0
axelvento axelvento 7 월 전
https://investors.iobiotech.com/news-events/news/news-details/2024/IO-Biotech-Announces-Abstract-Accepted-for-Presentation-at-the-2024-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting/default.aspx
👍️0
axelvento axelvento 8 월 전
IO Biotech was founded in 2014 and just 10 years into the journey we are in a pivotal phase III trial I think that’s quite fast
👍️0
axelvento axelvento 8 월 전
next catalyst-In November 2023, the company completed enrollment of 380 patients in its pivotal Phase 3 trial (IOB-013/KN-D18) of IO102-IO103 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in advanced melanoma. The primary endpoint of the pivotal Phase 3 trial is progression free survival (PFS). The PFS analysis is event-driven and will be conducted when 226 events have occurred in the trial, which the company estimates will take place in the second half of 2025. Additionally, a planned interim analysis of overall response rate (ORR) will be conducted when the first 225 randomized patients reach one year of treatment in June 2024. The outcome of this analysis is expected in the third quarter of 2024.
👍️0
Monksdream Monksdream 9 월 전
IOBT under $2
👍️0
Monksdream Monksdream 9 월 전
IOBT under $2
👍️0
Monksdream Monksdream 1 년 전
IOBT new 52 week low
👍️0
Monksdream Monksdream 1 년 전
IOBT new 52 week low
👍️0
Monksdream Monksdream 1 년 전
IOBT ubder $2
👍️0
AJ Freely AJ Freely 1 년 전
$IOBT - 👆Up 1.8% Pre-Market/ Current Price $2.00
Announces $75 Million Private Placement Financing
👍️0
The Night Stalker The Night Stalker 1 년 전
nice
👍️0
kzivann kzivann 1 년 전
Extremely heavy volume on good news. PPS down . Lower this AM. Watching

IOBT
👍️0
Phosphene Phosphene 3 년 전
IO Biotech’s (NASDAQ:IOBT ) lock-up period is set to end on Wednesday, May 4th.

https://www.defenseworld.net/2022/04/27/io-biotech-inc-s-lock-up-period-set-to-end-on-may-4th-nasdaqiobt.html
👍️0
conix conix 3 년 전
Bitoechs are waking up ---like they did last year.

I shopped for a number of sold out biotechs in December and picked and chose a number of sold out biotechs.

IOBT --I missed. But there are legs here. I have done well on four of my picks. Still waiting on two.

Time will tell.
👍️0
Phosphene Phosphene 3 년 전
IO Biotech Announces Third Clinical Collaboration with Merck to Evaluate IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Phase 2 Multi-Arm Basket Trial

IO Biotech to initiate a Phase 2 combination trial to explore safety and efficacy for treating multiple tumor types

https://www.globenewswire.com/news-release/2021/12/06/2346557/0/en/IO-Biotech-Announces-Third-Clinical-Collaboration-with-Merck-to-Evaluate-IO102-IO103-in-Combination-With-KEYTRUDA-pembrolizumab-as-First-Line-Treatment-in-a-Phase-2-Multi-Arm-Baske.html

👍️0
Eggplant Eggplant 3 년 전
What happened? IPO at $14/sh four weeks ago, and the stock has nearly folded in half. No news, and the only sellers should be the IPO buyers, right? Mystery.
👍️0
Work Harder Work Harder 3 년 전
I was right on the 7

for now

Yu tell wifeie

I appreciate her time

:}
👍️0
Phosphene Phosphene 3 년 전
Did Sunstone/Verland recoup initial seed?









👍️0
Staypositive1 Staypositive1 3 년 전
might wait till .035...lol
👍️0
Phosphene Phosphene 3 년 전
IO Biotech begins trading on Nasdaq Global Market today.

IPO pps is $14.

Thu, November 4, 2021, 11:52 PM.

https://finance.yahoo.com/news/io-biotech-inc-announces-pricing-035200314.html?fr=sycsrp_catchall

Sunstone and Novo Holdings involved.
👍️0
Phosphene Phosphene 3 년 전
EXPLORATORY PROJECT TO COMPARE IO BIOTECH ANTIGENS LINKED TO MYMETICS’ (MYMX) VIROSOMES IN A PRECLINICAL TUMOR MODEL

https://www.mymetics.com/media-center/exploratory-project-compare-io-biotech-antigens-linked-mymetics-virosomes-preclinical-tumor-model/


IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial

https://www.prnewswire.com/news-releases/io-biotech-announces-clinical-collaboration-with-msd-to-evaluate-io102-io103-with-keytruda-pembrolizumab-as-first-line-treatment-in-metastatic-melanoma-patients-in-a-phase-3-trial-301375679.html
👍️0
Phosphene Phosphene 3 년 전
Denmark's IO Biotech seeks $110M+ in Nasdaq debut.

https://pitchbook.com/newsletter/denmarks-io-biotech-seeks-110m-in-nasdaq-debut

https://www.fiercebiotech.com/biotech/io-biotech-raises-155m-to-trial-ido-and-pd-l1-cancer-vaccines

https://www.iobiotech.com/

The Food and Drug Administration (FDA) grants IO Biotech breakthrough therapy designation for IO102 and IO103 in combination with anti-PD-1 in unresectable/ metastatic melanoma

https://www.firstwordpharma.com/node/1783725?tsid=17
👍️0

최근 히스토리

NASDAQ
IOBT
IO Biotech
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유